Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) have emerged as a cornerstone in the management of type 2 diabetes mellitus (T2DM), offering glycemic control with favorable cardiovascular outcomes. The gene discussed is GLP1R; the disease is diabetes mellitus.